Stuart A. Arbuckle - 04 Feb 2025 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, COO
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
04 Feb 2025
Net transactions value
$0
Form type
4
Filing time
06 Feb 2025, 16:18:40 UTC
Previous filing
25 Jun 2024
Next filing
12 Feb 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Award $0 +14,624 +29% $0.000000 64,315 04 Feb 2025 Direct F1
transaction VRTX Common Stock Award $0 +8,448 +13% $0.000000 72,763 04 Feb 2025 Direct F2
holding VRTX Common Stock 140 04 Feb 2025 401(k)
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest on 02/26/2025.
F2 Represents earned performance shares with respect to a performance stock unit award granted on 02/07/2024 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest in installments beginning on 02/17/2025.